A Collaboration Sponsored by Partnerships For Change®
Every day, people with advanced cancer face treatments that often feel like guesswork. Genomic testing—widely used in cancer care—can match a small percentage of patients (≈10–15%) to a targeted therapy. But for the vast majority, it does not indicate which chemotherapy or targeted drugs will actually work. PACT is changing that.
Partnerships For Change® sponsors the Partnership for Advanced Cancer Treatment (PACT), a collaboration with SageMedic that brings forward a new generation of personalized cancer care. Instead of looking only at DNA, SageMedic’s Functional Precision Profiling (FPP) tests how a patient’s own live cancer cells respond to many therapies in the lab. It measures two critical effects—cell killing (cytotoxicity) and slowdown of growth (antiproliferation)—using a proprietary 3D microtumor platform that closely mimics the patient’s tumor environment.
This is not standard testing. It is actionable personalization, based on real drug response rather than predictions. PACT focuses on two core missions:
- Supporting Patients Who Need Help Now
No patient should be denied access to a test that may identify a more effective treatment. PACT provides education and financial assistance so eligible patients can receive the SAGE OncoTest. - Advancing Clinical Evidence
PACT partners with leading researchers to conduct clinical studies in advanced cancers. These studies aim to show that FPP can help patients live longer, feel better, and avoid ineffective treatments and unnecessary toxicity.
Building this evidence accelerates access and inclusion in mainstream care. PACT stands for compassion, equity, and scientific progress. By bringing functional precision oncology to patients who need it most, we are helping turn laboratory insights into better outcomes—today, not years from now. Together, we are shaping a future where personalized cancer treatment is based on how a patient’s own tumor responds, not just what its genes say.